Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Fei, Fei ^a   Lim, Min ^a   Schmidhuber, Sabine ^a,b   Moll, Jürgen ^c   Groffen, John ^a,d,e   Heisterkamp, Nora ^a,d,e  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^c Nerviano Medical Sciences ^*  (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aurora kinase inhibition; Co culture; Dasatinib, p53, Combination drug treatment; Drug resistance; Farnesyltransferase inhibitor, Lonafarnib; Ph positive; Stromal support

Indexed keywords

AURORA KINASE INHIBITOR; BCR ABL PROTEIN; DANUSERTIB; DNA; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOTHERAPY; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; MICE; MUTATION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; VINCRISTINE;

MUS;

EID: 84868617860     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-42     Document Type: Article

References (49)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178. 10.1056/NEJMra052603, 16407512.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004. 10.1056/NEJMoa022457, 12637609.
3. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives. Rev Clin Exp Hematol 2002, 6:142-160. discussion 200-142, 10.1046/j.1468-0734.2002.00066.x, 12196213.
4. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003, 349:1451-1464. 10.1056/NEJMra020777, 14534339.
5. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003, 40:4-10.
6. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004, 22:247-306. 10.1146/annurev.immunol.22.012703.104753, 15032571.
7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653. 10.1182/blood-2004-08-3097, 15618470.
8. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539. 10.1182/blood.V99.10.3530, 11986204.
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937. 10.1182/blood.V99.6.1928, 11877262.
10. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108:697-704. 10.1182/blood-2005-11-4687, 16597591.
11. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006, 16:92-99. 10.1016/j.gde.2005.11.002, 16343892.
12. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 2006, 66:11314-11322. 10.1158/0008-5472.CAN-06-1199, 17114238.
13. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401. 10.1126/science.1099480, 15256671.
14. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Canc Cell 2005, 7:129-141.
15. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003, 15:672-683. 10.1016/j.ceb.2003.10.013, 14644191.
16. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003, 4:842-854. 10.1038/nrm1245, 14625535.
17. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003, 22:451-464. 10.1023/A:1023789416385, 12884918.
18. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon?. Oncogene 2005, 24:5005-5015. 10.1038/sj.onc.1208752, 16049526.
19. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4:927-936. 10.1038/nrc1502, 15573114.
20. Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009, 15:6694-6701. 10.1158/1078-0432.CCR-09-1445, 2826106, 19825950.
21. Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol., Offic J Am Soc Clin Oncol 2009, 27:5094-5101.
22. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Canc Chemother Pharmacol 2011, 67:945-954.
23. Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther 2010, 9:661-672. 10.1158/1535-7163.MCT-09-1144, 20159992.
24. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brummendorf TH. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111:4355-4364. 10.1182/blood-2007-09-113175, 18268096.
25. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007, 6:3158-3168. 10.1158/1535-7163.MCT-07-0444, 18089710.
26. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007, 67:7987-7990. 10.1158/0008-5472.CAN-07-1825, 17804707.
27. Paquette RL, Sha NP, Sawyers CL, Martinelli G, John N, Chalukya M, Rocchetti M, Fiocchi C, Comis S, Capolongo L, et al. PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL. Blood (ASH Annual Meeting Abstracts) 2007, 110. Abstract 110.
28. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262-267. 10.1038/nm1003, 14981513.
29. Dai Y, Chen S, Venditti CA, Pei XY, Nguyen TK, Dent P, Grant S. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008, 112:793-804. 10.1182/blood-2007-10-116376, 2481545, 18505786.
30. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007, 110:2034-2040. 10.1182/blood-2007-02-073700, 17495131.
31. Carpinelli P, Moll J. Aurora kinases and their inhibitors: more than one target and one drug. Adv Exp Med Biol 2008, 610:54-73. 10.1007/978-0-387-73898-7_5, 18593015.
32. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661. 10.1021/jm049486a, 15615512.
33. Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009, 114:3459-3463. 10.1182/blood-2007-10-113969, 2765681, 19706883.
34. Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003, 12:851-862. 10.1016/S1097-2765(03)00392-7, 14580337.
35. Kim Y, Holland AJ, Lan W, Cleveland DW. Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E. Cell 142:444-455.
36. Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia 2009, 11:934-944. 2735802, 19724687.
37. Pan J, Yeung SC. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005, 65:9109-9112. 10.1158/0008-5472.CAN-05-2635, 16230362.
38. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007, 6:1317-1328. 10.1158/1535-7163.MCT-06-0703, 17431110.
39. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol 2004, 31:28-39.
40. Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 13:298-306.
41. Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell MR, Pulone B, Rincon A, et al. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia 2010, 25:1543-1547.
42. Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res 2011, 17:1140-1146. 10.1158/1078-0432.CCR-10-1878, 3049960, 21233404.
43. Cortes-Franco J, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Latini F, Capolongo L, Laffranchi B, Comis S. Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Haematologica 2009, 144:864.
44. Soverini S, Iacobucci I, Baccarani M, Martinelli G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007, 92:437-439. 10.3324/haematol.11248, 17488653.
45. Tuma RS. With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model. J Natl Canc Inst 2007, 99:192-194.
46. Fei F, Stoddart S, Groffen J, Heisterkamp N. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias. Mol Cancer Ther 2010, 9:1318-1327. 10.1158/1535-7163.MCT-10-0069, 2868097, 20388735.
47. Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V, Groffen J, Heisterkamp N. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer 2007, 6:67. 10.1186/1476-4598-6-67, 2169263, 17958915.
48. Mishra S, Zhang B, Groffen J, Heisterkamp N. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl. Leukemia 2004, 18:23-28. 10.1038/sj.leu.2403203, 14603339.
49. Zhang B, Groffen J, Heisterkamp N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. Leukemia 2007, 21:1189-1197. 10.1038/sj.leu.2404667, 17392819.